Search
Displaying 481–490 of 866 results for “vision connection”
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Beacon Stories
Adopted into a musical family, Miles Hoyt picked up a guitar at just four years old, and he hasn’t stopped playing since. Now Miles, who has Stargardt disease, and his parents are using music to bring their community together to raise funds for blinding diseases with their Raising Our Sights fundraiser, Smiles for Miles.
-
Foundation News
The May 9th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Foundation’s Reach Inspires Partnership for Nixon Family
Beacon StoriesAfter Janine’s diagnosis of an IRD caused by a mutation of the PRPH2 gene, she and her husband set out to learn and help all they could. So they started working with the Foundation Fighting Blindness and have launched the ‘PRPH2 and Associated Retinal Degenerations Program.’
-
Research News
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
The Inspiring Journey of an Endurance Athlete with Cone-Rod Dystrophy
Beacon StoriesDiagnosed with cone-rod dystrophy in his youth, Dan Berlin has defied all odds by becoming a global force in endurance sports and entrepreneurship. As an accomplished athlete, he has not only dominated marathons across the globe but also co-founded the Team See Possibilities organization, offering support to youth with blinding diseases.
-
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
Research News
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
